Cerebral microvascular rather than parenchymal amyloid-β protein pathology promotes early cognitive impairment in transgenic mice

Journal of Alzheimer's Disease

Volumn 38, Issue 3, 2014, Pages 621-632

  Xu, Wenjin ^a   Xu, Feng ^b   Anderson, Maria E ^a   Kotarba, AnnMarie E ^b   Davis, Judianne ^b   Robinson, John K ^a   Van Nostrand, William E ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Amyloid protein; cerebral microvascular; cognitive impairment; parenchymal; pathology; transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VESSEL; COGNITIVE DEFECT; MICROVASCULARIZATION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; TRANSGENIC MOUSE; WORKING MEMORY;

AMYLOID-Β PROTEIN; CEREBRAL MICROVASCULAR; COGNITIVE IMPAIRMENT; PARENCHYMAL; PATHOLOGY; TRANSGENIC MICE;

AGE FACTORS; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEIN E4; CEREBRAL CORTEX; HUMANS; MAZE LEARNING; MICE; MICE, TRANSGENIC; MICROVESSELS; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; PRESENILIN-1; REACTION TIME;

EID: 84889644123     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130758     Document Type: Article

References (80)

1. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766.
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
3. Cummings BJ, Cotman CW (1995) Image analysis of betaamyloid load in Alzheimer's disease and relation to dementia severity. Lancet 346, 1524-1528.
4. Haroutunian V, Perl DP, Purohit DP,Marin D, Khan K, Lantz M, Davis KL, Mohs RC (1998) Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol 55, 1185-1191.
5. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46, 860-866.
6. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283, 1571-1577.
7. Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD (2001) Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol 58, 2025-2032.
8. Bussiere T, Friend PD, Sadeghi N,Wicinski B, Lin GI, Bouras C, Giannakopoulos P, Robakis NK, Morrison JH, PerlDP, Hof PR (2002) Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease. Neuroscience 112, 75-91.
9. Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 12, 295-312.
10. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
11. Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, SaundersAM(1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55, 326-335.
12. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, Morrison JH, Gold G, Hof PR (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 1495-1500.
13. Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO (2004) Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease Pro-CAA statement. Neurobiol Aging 25, 589-597.
14. Haglund M, Kalaria R, Slade JY, Englund E (2006) Differential deposition of amyloid beta peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia. Acta Neuropathol 111, 430-435.
15. Eikelenboom P, Veerhuis R, Familian A, Hoozemans JJM, van Gool WA, Rozemuller AJM (2008) Neuroinflammation in plaques and vascular -Amyloid disorders: Clinical and therapeutic implications. Neurodegener Dis 5, 190-193.
16. Thal DR, Griffin WST, Braak H (2008) Parenchymal and vascular A- deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med 12, 1848-1862.
17. Richard E, Carrano A, Hoozemans JJ, van Horssen J, van Haastert ES, Eurelings LS, de Vries HE, Thal DR, Eikelenboom P, van GoolWA, Rozemuller JM (2010) Characteristics of dyshoric capillary cerebral amyloid angiopathy. J Neuropathol Exp Neurol 69, 1158-116&
18. Natte R, Maat-Schieman ML, Haan J, Bornebroek M, Roos RA, van Duinen SG (2001) Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. Ann Neurol 50, 765-772.
19. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ (2002) Cerebral amyloid angiopathy and cognitive function: The HAAS autopsy study. Neurology 58, 1629-1634.
20. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD (2003) Vascular pathology in Alzheimer's disease: Correlation of cerebral amyloid angiopathy and arteriosclerosis/ lipohyalinosis with cognitive decline. J Neuropath Exp Neurol 62, 1287-1301.
21. Greenberg SM, Gurol ME, Rosand J, Smith EE (2004) Amyloid angiopathy-related vascular cognitive impairment. Stroke 35, 2616-2619.
22. Bailey TL, Rivara CB, Rocher AB, Hof PR (2004) The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res 26, 573-578.
23. Haglund M, Sjobeck M, Englund E (2004) Severe cerebral amyloid angiopathy characterizes an underestimated variant of vascular dementia. Dement Geriatr Cogn Disord 18, 132-137.
24. HaglundM,Passant U, SjobeckM,Ghebremedhin E, Englund E (2006) Cerebral amyloid angiopathy and cortical microinfarcts as putative substrates of vascular dementia. Int J Geriatr Psychiatry 21, 681-687.
25. Thal DR, Griffin WS, Braak H (2008) Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med 12, 1848-1862.
26. Marchant NL, Reed BR, Sanossian N, Madison CM, Kriger S, Dhada R, Mack WJ, Decarli C,WeinerMW, Mungas DM, Chui HC, Jagust WJ (2013) The aging brain and cognition: Contribution of vascular injury and A- To mild cognitive dysfunction. JAMA Neurol 70, 488-495.
27. Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, ZlokovicBV,Van NostrandWE(2004) Early-onset and robust cerebral miscrovascular accumulation of amyloid - protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid. J Biol Chem 279, 20296-20306.
28. Miao J, Xu F, Otte-Höller I, Verbeek MM, Davis J, Van Nostrand WE (2005) Cerebral microvascular A- deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant A-PP. Am J Path 167, 505-515.
29. Xu F, Grande AM, Robinson JK, Previti ML, Davis J, Van Nostrand WE (2007) Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant A-PP transgenic mice. Neuroscience 146, 98-107.
30. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal -Amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140.
31. Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R, Disterhoft JF, Vassar R (2007) BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis 26, 134-145.
32. OhnoM(2009) Failures to reconsolidate memory in a mouse model of Alzheimer's disease. Neurobiol Learn Mem 92, 455-459.
33. Barnes CA (1979) Memory deficits associated with senescence: A neuropsychological and behavioral study in the rat. J Comp Physiol Psychol 93, 74-104.
34. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L (1997) Amyloid precursor protein processing and A-42 deposition in a transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 94, 1550-1555.
35. DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM (2002) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 99, 10843-10848.
36. Yang T, Hong S, O'Malley T, Sperling RA,Walsh DM, Selkoe DJ (2013) New ELISAs with high specificity for soluble oligomers of amyloid -protein detect natural A- oligomers in human brain but not in CSF. Alzheimers Dement 9, 99-112.
37. Fan R, Xu F, Previti ML, Davis J, Grande AM, Robinson JK,Van NostrandWE(2007) Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J Neurosci 27, 3057-3063.
38. Davis-Salinas J, Saparito-Irwin SM, Donovan FM, Cunningham DD, Van Nostrand WE (1994) Thrombin receptor activation induces secretion and nonamyloidogenic processing of amyloid -protein precursor. J Biol Chem 269, 22623-22627.
39. Long JM, Kalehua AN, Muth NJ, Calhoun ME, Jucker M, Hengemihle JM, Ingram DK, Mouton PR (1998) Stereological estimation of total microglia number in mouse hippocampus. J Neurosci Methods 84, 101-108.
40. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-Term potentiation in vivo. Nature 416, 535-539.
41. De Felice FG, Viera MNN, Saraiva LM, Figueroa-Villar JD, Garci-Abreu J, Liu R, Chang L, Klein WL, Ferreira ST (2004) Targeting the neurotoxic species in Alzheimer's disease: Inhibitors of A- oligomerization. FASEB J 18, 1366-1372.
42. Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27, 570-575.
43. Ono K, Condron MM, Teplow DB (2009) Structureneurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A 106, 14745-14750.
44. Kayed R, Head E, Sarsoza F, Saing T, CotmanCW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2, 18.
45. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberberg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J (1995) Alzheimer-Type neuropathology in transgenic mice overexpressing V717F -Amyloid precursor protein. Nature 373, 523-527.
46. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, A- elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
47. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold K-H, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M (1999) Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A 96, 14088-14093.
48. ChishtiMA,Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette, C., Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, George-Hyslop PS, Westaway D (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276, 21562-21570.
49. De Felice FG, Viera MNN, Saraiva LM, Figueroa-Villar JD, Garci-Abreu J, Liu R, Chang L, Klein WL, Ferreira ST (2004) Targeting the neurotoxic species in Alzheimer's disease: Inhibitors of A- oligomerization. FASEB J 18, 1366-1372.
50. Findeis MA (2007) The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther 116, 266-286.
51. Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 278, 11612-11622.
52. Paravastua AK, Leapman RD, Yau WM, Tycko R (2008) Molecular structural basis for polymorphism in Alzheimer's -Amyloid fibrils. Proc Natl Acad Sci U S A 105, 18349-18354.
53. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, Elliott JI, Van Nostrand WE, Smith SO (2010) Structural conversion of neurotoxic amyloid-(1-42) oligomers to fibrils. Nat Struct Mol Biol 17, 561-567.
54. Urbanc B, Cruz J, Le R, Sanders J, Hsiao Ashe K, Duff K, Stanley HE, Irizarry MC, Hyman BT (2002) Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc Natl Acad Sci U S A 99, 13990-13995.
55. Van Nostrand WE, Melchor J, Ruffini L (1998) Pathogenic cell surface amyloid -protein fibril assembly in cultured human cerebrovascular smooth muscle cells. J Neurochem 70, 216-223.
56. Rogers J, Cooper NR,Webster S, Schulz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Lieberburg I (1992) Complement activation by -Amyloid in Alzheimer's disease. Proc Natl Acad Sci U S A 89, 10016-10020.
57. Tacnet-Delorme P, Chevallier S, Arlaud GJ (2001) -Amyloid fibrils activate the C1 complex of complement under physiological conditions: Evidence for a binding site for A- on the C1q globular regions. J Immunol 167, 6374-6381.
58. Rozemuller AJ, van Gool WA, Eikelenboom P (2005) The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer's disease: Therapeutic implications. Curr Drug Targets CNS Neurol Disord 4, 223-233.
59. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE (2009) CD14 and toll-like receptors 2 and are required for fibrillar A-stimulated microglial activation. J Neurosci 29, 11982-11992.
60. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GT, Luyendijk W, Frangione B (1990) Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124-1126.
61. Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM(2001) Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 49, 697-705.
62. Davis J, Van NostrandWE(1996) Enhanced pathologic properties of Dutch-Type mutant amyloid beta-protein. Proc Natl Acad Sci U S A 93, 2996-3000.
63. Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, Frangione B, Ghiso J (2000) Substitutions at codon 22 of Alzheimer's A- peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem 275, 27110-27116.
64. Melchor JP, McVoy L, Van Nostrand WE (2000) Charge alterations of E22 enhance the pathogenic properties of the amyloid beta-protein. J Neurochem 74, 2209-2212.
65. Van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW (2001) Pathogenic effects of D23N Iowa mutant amyloid beta-protein. J Biol Chem 276, 32860-32866.
66. Verbeek MM, de Waal RM, Schipper JJ, Van Nostrand WE (1997) Rapid degeneration of cultured human brain pericytes by amyloid beta protein. J Neurochem 68, 1135-1141.
67. Wang Z, Natte R, Berliner JA, van Duinen SG, Vinters HV (2000) Toxicity of Dutch (E22Q) and Flemish (A21G) mutant amyloid - proteins to human cerebral microvessel and aortic smooth muscle cells. Stroke 31, 534-538.
68. Werring DJ, Gregoire SM, Cipolotti L (2010) Cerebral microbleeds and vascular cognitive impairment. J Neurol Sci 299, 131-135.
69. Pluta R, Ulamek M, JablonskiM(2010) Consideration of the ischaemic basis and treatment of Alzheimer's disease. Folia Neuropathol 48, 11-26.
70. Hedden T, Mormino EC, Amariglio RE, Younger AP, Schultz AP, Becker JA, Buckner RL, Johnson KA, Sperling RA, Rentz DM (2012) Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci 32, 16233-16242.
71. Marchant NL, Reed BR, DeCarli CS, Madison CM, Weiner MW, Chui HC, Jagust WJ (2012) Cerebrovascular disease, -Amyloid, and cognition in aging. Neurobiol Aging 33, 25-36.
72. Zhang M, Chen M,Wang Q, YunW, Zhang Z, Yin Q, Huang Q, ZhuW(2013) Relationship between cerebral microbleeds and cognitive function in lacunar infarct. J Intl Med Res 41, 347-355.
73. Marchant NL, Reed BR, Sanossian N, Madison CM, Kriger S, Dhada R, Mack WJ, DeCarli C, Weiner MW, Mungas DM, Chui HC, Jagust WJ (2013) The aging brain and cognition: Contribution of vascular injury and A- To mild cognitive dysfunction. JAMA Neurol 70, 488-495.
74. Provenzano FA, Muraskin J, Tosto G, Narkhede A, WassermanBT, GriffithEY, GuzmanVA,Meier IB, Zimmerman ME, Brickman AM, Alzheimer's Disease Neuroimaging Initiative (2013) White matter hyperintensities and cerebral amyloidosis: Necessary and sufficient for clinical expression of Alzheimer's disease? JAMA Neurol 70, 455-461.
75. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357, 169-175.
76. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ (2002) Cerebral amyloid angiopathy and cognitive function. Neurology 58, 1629-1634.
77. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD (2003) Vascular pathology in Alzheimer's disease: Correlation of cerebral amyloid angiopathy and arteriosclerosis/ lipohyalinosis with cognitive decline. J Neuropath Exp Neurol 62, 1287-1301.
78. Attems J, Jellinger KA (2004) Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology - A pilot study. Acta Neuropathol 107, 83-90.
79. Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, Carlson GA, Iadecola C (2005) NADPH oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid - peptide. J Neurosci 25, 1769-1777.
80. Park L, Zhou P, Koizumi K, El Jamal S, Previti ML, Van Nostrand WE, Carlson G, Iadecola C (2013) Stroke 44, 198-204.